B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co

Joint marketing of CytoSorb® with B. Braun’s newest OMNI® blood purification platform will offer greater access of this advanced treatment of deadly inflammation to critically ill patients. MELSUNGEN, Germany and MONMOUTH JUNCTION, N.J., March 2, 2021 /PRNewswire/ — B. Braun Avitum AG, a leading manufacturer of medical devices and pharmaceutical products and services and CytoSorbents Corporation […]

In this image released on Tuesday, March 2, 2021, the OMNI® extracorporeal platform is intended to perform continuous blood purification treatments and therapeutic plasma exchange. The OMNI® in combination with OMNIset®* disposable

B. Braun Melsungen AG Accelerates Digital Healthcare Innovations with MuleSoft - Salesforce

Memic Receives FDA Authorization for Hominis® Robot-Assisted

In this image released on Tuesday, March 2, 2021, the CytoSorb® adsorber is used in critical care for the extracorporeal removal of cytokines and inflammatory mediators from the bloodstream. B. Braun Avitum

Organization, Facts & Figures

Your career at B Braun Avitum (Pty) LTD

Promoting Management and Leadership

B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI® Continuous Blood Purification Platform with CytoSorb® - Cytosorbents

In this image released on Tuesday, March 2, 2021, the CytoSorb® adsorber is used in critical care for the extracorporeal removal of cytokines and inflammatory mediators from the bloodstream. B. Braun Avitum

Memic Receives FDA Authorization for Hominis® Robot-Assisted

Organization, Facts & Figures

Stock Market News 2021-03-02

Press Releases - Cytosorbents

Acute Kidney Injuries Market 2031 - $3.01 Billion Revenue Forecast